全身性エリテマトーデス及びループス腎炎：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Prognosis 29
3.3 Quality of Life 29
3.4 Symptoms 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 31
4.1.1 Women are at a higher risk of developing SLE than men 32
4.1.2 Caucasians are at lower risk of developing SLE than other ethnicities 32
4.1.3 Familial history has been associated with an increased risk of developing SLE 34
4.1.4 Certain occupational and environmental exposures trigger SLE 34
4.2 Global Trends 36
4.2.1 US 36
4.2.2 5EU 37
4.2.3 Japan 40
4.3 Forecast Methodology 41
4.4 Sources Used 44
4.4.1 US 44
4.4.2 France 45
4.4.3 Germany 45
4.4.4 Italy 45
4.4.5 Spain 46
4.4.6 UK 47
4.4.7 Japan 48
4.5 Sources Not Used 49
4.5.1 US 49
4.5.2 5EU 49
4.5.3 Japan 50
4.6 Forecast Assumptions and Methods 50
4.6.1 US 51
4.6.2 5EU 51
4.6.3 Japan 55
4.7 Epidemiological Forecast of SLE (2012-2022) 56
4.7.1 Diagnosed Prevalent Cases of SLE 56
4.7.2 Age-Specific Prevalent Cases of SLE 58
4.7.3 Sex-Specific Prevalent Cases of Diagnosed SLE 60
4.7.4 Age-Standardized Prevalence of SLE 62
4.7.5 Diagnosed Prevalent Cases of LN 63
4.7.6 Prevalent Cases of LN, Segmented by Class 65
4.8 Discussion 67
4.8.1 Conclusions on Epidemiology Trends 67
4.8.2 Limitations of the Analysis 68
4.8.3 Strengths of the Analysis 69
5 Disease Management 71
5.1 Diagnosis Overview 71
5.1.1 SLE Diagnosis 71
5.1.2 LN Diagnosis 74
5.2 Treatment Overview 76
5.3 US 80
5.3.1 Diagnosis 80
5.3.2 Clinical Practice 81
5.4 France 83
5.4.1 Diagnosis 83
5.4.2 Clinical Practice 83
5.5 Germany 85
5.5.1 Diagnosis 85
5.5.2 Clinical Practice 85
5.6 Italy 87
5.6.1 Diagnosis 87
5.6.2 Clinical Practice 87
5.7 Spain 89
5.7.1 Diagnosis 89
5.7.2 Clinical Practice 89
5.8 UK 91
5.8.1 Diagnosis 91
5.8.2 Clinical Practice 91
5.9 Japan 93
5.9.1 Diagnosis 93
5.9.2 Clinical Practice 93
6 Competitive Assessment 95
6.1 Overview 95
6.2 Strategic Competitor Assessment 96
6.3 Product Profiles – Major Brands 97
6.3.1 Antimalarial Therapy (numerous brand names) 97
6.3.2 Steroids (numerous brand names) 102
6.3.3 Methotrexate (numerous brand names) 108
6.3.4 Mycophenolate Mofetil (numerous brand names) 113
6.3.5 Cyclophosphamide (numerous brand names) 118
6.3.6 Azathioprine (numerous brand names) 123
6.3.7 Calcineurin Inhibitors (numerous brand names) 127
6.3.8 Benlysta (belimumab) 132
6.3.9 Rituxan (rituximab) 141
6.3.10 Minor Therapeutic Classes 146
7 Opportunity and Unmet Need 147
7.1 Overview 147
7.2 Unmet Needs 148
7.2.1 Efficacious Treatments with Reduced Side Effects 148
7.2.2 Management of LN 150
7.2.3 Improvement in Patients’ Mortality 151
7.2.4 Management of Lupus Comorbidities 151
7.2.5 Sensitive and Reliable Biomarkers 152
7.2.6 Physicians’ Education and Public Awareness of SLE 153
7.2.7 Unmet Needs Gap Analysis 153
7.3 Opportunities 154
7.3.1 Efficacious and Safe Therapies 154
7.3.2 Therapies Targeting LN Patients 155
7.3.3 Treatments for Common Lupus Comorbidities 156
7.3.4 Discovery of Biomarkers 156
8 Pipeline Assessment 157
8.1 Overview 157
8.2 Clinical Trial Mapping 158
8.2.1 Clinical Trials by Country 158
8.2.2 Clinical Trials by Phase and Trial Status 159
8.3 Promising Drugs in Clinical Development 161
8.3.1 Blisibimod (A-623) 164
8.3.2 Tabalumab (LY-2127399) 171
8.3.3 Atacicept 178
8.3.4 Epratuzumab 184
8.3.5 Lupuzor (rigerimod) 192
8.3.6 Orencia (abatacept) 198
9 Current and Future Players 205
9.1 Overview 205
9.2 Trends in Corporate Strategy 207
9.3 Company Profiles 209
9.3.1 GlaxoSmithKline 209
9.3.2 Roche 211
9.3.3 UCB 214
9.3.4 Eli Lilly and Company 216
9.3.5 Bristol-Myers Squibb 218
9.3.6 Anthera Pharmaceuticals 219
9.3.7 ImmuPharma 221
9.3.8 Merck Serono 222
10 Market Outlook 224
10.1 Global Markets 224
10.1.1 Forecast 224
10.1.2 Drivers and Barriers – Global Issues 231
10.2 US 234
10.2.1 Forecast 234
10.2.2 Key Events 238
10.2.3 Drivers and Barriers 238
10.3 France 241
10.3.1 Forecast 241
10.3.2 Key Events 245
10.3.3 Drivers and Barriers 245
10.4 Germany 247
10.4.1 Forecast 247
10.4.2 Key Events 251
10.4.3 Drivers and Barriers 251
10.5 Italy 253
10.5.1 Forecast 253
10.5.2 Key Events 257
10.5.3 Drivers and Barriers 257
10.6 Spain 259
10.6.1 Forecast 259
10.6.2 Key Events 263
10.6.3 Drivers and Barriers 263
10.7 UK 265
10.7.1 Forecast 265
10.7.2 Key Events 269
10.7.3 Drivers and Barriers 269
10.8 Japan 271
10.8.1 Forecast 271
10.8.2 Key Events 275
10.8.3 Drivers and Barriers 275
11 Appendix 278
11.1 Bibliography 278
11.2 Abbreviations 293
11.3 Methodology 298
11.4 Forecasting Methodology 298
11.4.1 Diagnosed SLE and LN Patients 298
11.4.2 Percent Drug-Treated Patients 299
11.4.3 Drugs Included in Each Therapeutic Class 299
11.4.4 Launch and Patent Expiry Dates 299
11.4.5 General Pricing Assumptions 300
11.4.6 Individual Drug Assumptions 301
11.4.7 Generic Erosion 304
11.4.8 Pricing of Pipeline Agents 305
11.5 Physicians and Specialists Included in this Study 306
11.6 Primary Research – Prescriber Survey 308
11.7 About the Authors 309
11.7.1 Analysts 309
11.7.2 Epidemiologist 310
11.7.3 Global Head of Healthcare 310
11.8 About GlobalData 311
11.9 Disclaimer 311